Cibler les cellules sénescentes: Une révolution dans le traitement des pathologies ostéo-articulaires

[en] Our societies are facing with the emergence of an exponential number of patients with age-related degenerative chronic diseases such as osteoarthritis or osteoporosis. The “better” aging will thus be at the center of the next medical challenges in order to delay the loss of independence of the elderly and reduce costs of our health services. Over the last 5 years, based on innovative mouse models or in vitro studies, several research teams have demonstrated that many age-related degenerative diseases have in common a deleterious accumulation of so-called senescent cells in their respective deficient tissues. Thus, under the concept of senolysis, it has been proposed to target pharmacologically in vivo these cells to eliminate them and thus delay the emergence of these chronic diseases of the elderly subject. We propose here to summarize the recent strategies applied for the identification of novel senolytics and their uses in osteoarthritis and osteoporosis therapies. © 2018 EDP Sciences. All rights reserved.

Disciplines :

Rheumatology

Author, co-author :

Tachikart, Y.; IRMB (institut de médecine régénératrice et de biothérapie de Montpellier), Inserm U1183, Univ Montpellier, 80, avenue Augustin Fliche, Montpellier, 34298, France

MALAISE, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de rhumatologie

Constantinides, M.; IRMB (institut de médecine régénératrice et de biothérapie de Montpellier), Inserm U1183, Univ Montpellier, 80, avenue Augustin Fliche, Montpellier, 34298, France

Jorgensen, C.; IRMB (institut de médecine régénératrice et de biothérapie de Montpellier), Inserm U1183, Univ Montpellier, 80, avenue Augustin Fliche, Montpellier, 34298, France, Service de rhumatologie, CHU La Peyronie, Montpellier, 34090, France

Brondello, J.-M.; IRMB (institut de médecine régénératrice et de biothérapie de Montpellier), Inserm U1183, Univ Montpellier, 80, avenue Augustin Fliche, Montpellier, 34298, France

Language :

French

Title :

Cibler les cellules sénescentes: Une révolution dans le traitement des pathologies ostéo-articulaires

Alternative titles :

[en] Senescent cells: A target in osteo-articular diseases

Publication date :

2018

Journal title :

MS. Medecine Sciences

ISSN :

0767-0974

eISSN :

1958-5381

Publisher :

Editions EDK

Volume :

Issue :

6-7

Pages :

547-553

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 19 January 2022

Statistics

Number of views

42 (5 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25: 585-621.
He S, Sharpless NE. Senescence in health and disease. Cell 2017; 169: 1000-11.
Childs BG, Gluscevic M, Baker DJ, et al. Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov 2017; 16: 718-35.
Coppe JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008; 6: 2853-68.
Muñoz-Espín D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol 2014; 15: 482-96.
Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of cellular senescence. Trends Cell Biol 2018.
Vicente R, Mausset-Bonnefont AL, Jorgensen C, et al. Cellular senescence impact on immune cell fate and function. Aging Cell 2016; 15: 400-6.
Demaria M, Ohtani N, Youssef SA, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell 2014; 31: 722-33.
Yun MH, Davaapil H, Brockes JP. Recurrent turnover of senescent cells during regeneration of a complex structure. Elife 2015; 4.
Jeon OH, Kim C, Laberge RM, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med 2017; 23: 775-81.
Farr JN, Xu M, Weivoda MM, et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med 2017; 23: 1072-9.
García-Prat L, Martínez-Vicente M, Perdiguero E, et al. Autophagy maintains stemness by preventing senescence. Nature 2016; 529: 37-42.
Childs BG, Baker DJ, Wijshake T, et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 2016; 354: 472-7.
Baker DJ, Childs BG, Durik M, et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 2016; 530: 184-9.
Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011; 479: 232-6.
Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58: 26-35.
Scanzello CR, Goldring SR. The role of synovitisino steo arthritis pathogenesis. Bone 2012; 51: 249-57.
Yu D, Xu J, Liu F, et al. Subchondral bone changes and the impacts on joint pain and articular cartilage degeneration in osteoarthritis. Clin Exp Rheumatol 2016; 34: 929-34.
Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992; 2: 285-9.
Bass E, French DD, Bradham DD, Rubenstein LZ. Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol 2007; 17: 514-9.
Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J Bone Miner Res 2007; 22: 1479-91.
Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res 2014; 29: 1-23.
Farr JN, Fraser DG, Wang H, et al. Identification of senescent cells in the bone microenvironment. J Bone Miner Res 2016; 31: 1920-9.
Chinta SJ, Woods G, Demaria M, et al. Cellular senescence is induced by the environmental neurotoxin paraquat and contributes to neuropathology linked to Parkinson’s disease. Cell Rep 2018; 22: 930-40.
Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 2015; 14: 644-58.
Fuhrmann-Stroissnigg H, Ling YY, Zhao J, et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat Commun 2017; 8: 422.
Kochetkova EY, Blinova GI, Bystrova OA, et al. Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway. Aging (Albany NY) 2017; 9: 2352-75.
Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 2017; 169: 132-47.e16.
Chang J, Wang Y, Shao L, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 2016; 22: 78-83.
Yosef R, Pilpel N, Tokarsky-Amiel R, et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun 2016; 7: 11190.
Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 2016; 15: 428-35.
Pan J, Li D, Xu Y, et al. Inhibition of Bcl-2/xl with ABT-263 selectively kills senescent type II pneumocytes and reverses persistent pulmonary fibrosis induced by ionizing radiation in mice. Int J Radiat Oncol Biol Phys 2017; 99: 353-61.
Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-41.
Dörr JR, Yu Y, Milanovic M, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 2013; 501: 421-5.
McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the nonsurgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22: 363-88.
Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-59.
Goy E, Abbadie C. Sénescence et cancer: double jeu. Med Sci (Paris) 2018; 34: 223-30.
Chauvet V, Jouaville S, Garbez N, Martins I. L’élimination des cellules sénescentes: vers un avenir meilleur ? Med Sci (Paris) 2016; 32: 1030-3.